Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Symbio Pharmaceuticals: Moving Ahead On All Fronts

By Edison Stock MarketsFeb 27, 2017 05:29AM ET
www.investing.com/analysis/symbio-pharmaceuticals---moving-ahead-on-all-fronts-200176990
Symbio Pharmaceuticals: Moving Ahead On All Fronts
By Edison   |  Feb 27, 2017 05:29AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

During 2017 we expect updates on all three of SymBio’s main assets. We expect Treakisym sales growth via partner Eisai Co., Ltd. (T:4523) following approvals during 2016 in new indications, which could more than double the current levels (¥4.7bn). For pipeline assets IONSYS and rigosertib, data from ongoing trials could become available during H217, which will shape the future development pathways. We also expect Symbiox Investment & Trading Co Ltd (BO:SYMB) to remain focused on in-licensing further opportunities to complement its existing pipeline. This could help drive future operating leverage if SymBio evolves into a commercial entity, possibly from 2020. We value SymBio at ¥19.7bn.

SymBio Pharmaceuticals
SymBio Pharmaceuticals

On track to maximise Treakisym’s potential

During 2016 SymBio received additional approvals for Treakisym in chronic lymphocytic leukaemia (CLL) and first-line low-grade non-Hodgkin’s lymphoma (NHL) and mantle cell lymphoma (MCL). These represent patient markets in Japan of around 7,800, compared to around 4,700 patients with relapsed or refractory (r/r) low-grade NHL/MCL, where sales have been generated to date (¥4,200m in 2016) via partner Eisai. Hence, we believe these additional indications could more than double current Treakisym sales and we expect an uplift during 2017.

To read the entire report Please click on the pdf File Below

Symbio Pharmaceuticals: Moving Ahead On All Fronts
 

Related Articles

Al Brooks
Emini Weak After June FOMC By Al Brooks - Jun 18, 2021

Emini Daily Chart– Fell below Wednesday’s low, but reversed up and closed just above open. – Yesterday is an Emini High 1 buy signal bar, but after two big bear days, and without a...

Symbio Pharmaceuticals: Moving Ahead On All Fronts

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email